NCT06821399 Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus
| NCT ID | NCT06821399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yufan Wang |
| Condition | Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,920 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,920 participants in total. It began in 2025-02-01 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to integrate clinical indicators and features of fundus images, combined with metabolomics, to construct an early warning model for diabetic retinopathy (DR) in type 2 diabetes. By combining clinical indicators with metabolomics, the investigators aim to establish a precise DR typing model based on the age of diabetes onset (early-onset diabetes, late-onset diabetes) and based on the coexistence with two types of diabetic macrovascular complications. A multidisciplinary collaboration will be conducted for comprehensive management of DR to control the progression of moderate-stage DR. Cloud-based patient rooms combined with continuous glucose monitoring (CGM) will further explore the role of integrated diabetes retinopathy ward management models in the management of patients undergoing diabetes retinopathy surgery, pioneering a new model for the management of advanced DR.
Eligibility Criteria
Inclusion Criteria: * Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)"; * Aged between 20 and 79 years old, without other severe underlying diseases; ③ Possesses full cognitive and literacy abilities; ④ Volunteers to participate in this study and are willing to sign an informed consent form. Exclusion Criteria: * Those who have been diagnosed with type 1 or other types of diabetes; * Those with severe cardiac, pulmonary, hepatic, or renal insufficiency; * Those with mental confusion, speech disorders, or dementia, etc.; * Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant; * Those with a recent history of surgery, trauma, acute major vascular complications, or infectious diseases.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06821399 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 79 Years, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06821399 currently recruiting?
Yes, NCT06821399 is actively recruiting participants. Contact the research team at guliping1980@126.com for enrollment information.
Where is the NCT06821399 trial being conducted?
This trial is being conducted at Lanzhou, China, Shanghai, China, Shenyang, China.
Who is sponsoring the NCT06821399 clinical trial?
NCT06821399 is sponsored by Yufan Wang. The trial plans to enroll 2,920 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.